The renal collecting duct is a site of insulin-like growth factor I (IGF I) synthesis. Epidermal growth factor (EGF) is also synthesized within the kidney in the thick ascending limb of
Introduction
The renal collecting duct is a site of insulin-like growth factor I (IGF I)' synthesis. IGF I of kidney origin is thought to regulate 1 . Abbreviations used in this paper: EGF and hEGF, epidermal growth factor and recombinant human EGF; GH and bGH, growth hormone and bovine GH; IGF I, insulin-like growth factor I; Ins-P3, inositol trisphosphate.
renal transport, metabolic, and growth processes (1) . As in nonrenal tissues, growth hormone (GH) stimulates renal IGF I gene expression. This occurs via a direct action on collecting duct cells (2) . The existence offactors other than GH that regulate IGF I gene expression in kidney is demonstrated by the findings of increased renal IGF I production under conditions where GH cannot play a causative role. Two such conditions are compensatory hypertrophy after unilateral nephrectomy (3) and early experimental diabetes mellitus (4) (5) (6) . The identity offactors other than GH that regulate IGF I expression in these or other states is unknown.
Epidermal growth factor (EGF), like IGF I, is produced in kidney and affects renal transport, metabolism, and growth. The sites ofrenal EGF synthesis are the thick ascending limb of Henle's loop and the distal convoluted tubule (7) . Because it is synthesized in distal portions of the kidney, renal EGF is thought to act upon structures in the collecting duct. The potential for EGF to regulate IGF I expression at this site is provided by the finding that EGF stimulates the production of somatomedin C (IGF I) by cultured human fibroblasts (8) . To ascertain whether EGF exerts a similar action in kidney, we performed a series of experiments using collecting ducts isolated from rat kidney: (a) we determined whether EGF "signal" transduction occurs in plasma membranes prepared from collecting ducts; (b) we determined whether EGF stimulates IGF I production in suspensions ofcollecting ducts; and (c) we determined whether EGF affects levels of IGF I mRNA in these suspensions. Our findings show that EGF acts directly in isolated collecting duct to enhance IGF I gene expression. It is possible that EGF produced in the thick ascending limb of Henle's loop or distal tubule acts directly upon collecting duct in vivo to enhance IGF I production, as part of an intrarenal EGF-IGF I axis. Certain ofthe actions ofEGF on kidney could be mediated by IGF I.
Methods
Experimental animals and isolation oftissues. Male Sprague-Dawley rats aged 12 wk weighing -250 g were used for experiments. Collecting ducts from rat kidneys were isolated using methodology identical to that employed in previous studies (2) . In brief, renal medulla was removed from kidneys and placed in ice-cold modified Ringer's solution consisting of 118 mM NaCl, 16 mM Hepes, 17 mM Na-Hepes, 14 mM glucose, 3.2 mM KCI, 2.5 mM CaCl2, and 1.8 mM KH2P04, pH 7.4. The tissue was minced, gassed with room air, and incubated at 370C in After an additional 45 min, the suspension was centrifuged atAl75 g for 2 min, the supernatant was discarded, and the pellet was resuspended in buffer without DNAse. Centrifugation and resuspension were repeated twice. Plasma membranes were prepared from isolated collecting ducts as described before (9) . We have shown that these membranes are enriched for arginine vasopressin-stimulated adenylate cyclase activity, but not for parathyroid hormone-stimulated adenylate cyclase (9) . Measurement ofphospholipase C activity. Phospholipase C activity associated with isolated collecting duct membranes was evaluated by measuring levels ofinositol trisphosphate (Ins-P3) in membrane suspensions as in previous studies (10) . Membranes (1 mg of protein) were suspended in 25 mM sucrose, 130 mM NaCl, 500,uM EGTA, and 50 mM Tris-HCl. Sufficient CaC12 was added so that the concentrations of free calcium was 200 nM. Suspensions were incubated for 15 s in the absence ofadded hormone or in the presence ofvarying concentrations of recombinant human epidermal growth factor (hEGF) (Upstate Biotechnology Inc., Lake Placid, NY, or Boeringer Mannheim Biochemicals). After incubation, membranes were extracted with 1 ml ofchloroform/methanol 2:1 (vol/vol), containing 2.4 M HC1. To measure Ins-P3 originating. from membranes, water-soluble inositol phosphates contained in the methanol layer of the extraction mixture were separated by high-performance liquid chromatography (HPLC). The Ins-P3 peak was desalted, concentrated, and dephosphorylated, and free myoinositol was measured using an enzymatic fluorometric assay.
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Measurement ofIGF I mRNA in isolated collecting ducts. To collecting ducts suspended in Ham's F12/Dulbecco's modified Eagle's medium as described above, was added 10-6 M hEGF, bGH, or no peptide. After 2 h of incubation at 37°C, collecting ducts were pelleted by centrifugation. Total cellular RNA was isolated using RNAzol B (Cinna/Biotecx Laboratories, Friendswood, TX). 100 Mg of collecting duct RNA routinely were isolated from eight kidneys. The integrity of RNA samples was evaluated using agarose/formaldehyde gel chromatography and its quantity was determined spectrophotometrically as before (2, 9) . Solution-hybridization nuclease-protection assays for IGF I or IGF II mRNA were performed as previously described (9) . A mRNA probe derived from a subclone of rat IGF I exon 3 or a probe derived from a subclone consisting of most of the first protein-coding exon of rat IGF II and adjacent intron sequences was used in these experiments. A 182 nucleotide portion ofthe former probe is protected by IGF I mRNA. The protected IGF II fragment appears as a doublet of 151-152 bases (9) . The probes were synthesized in an antisense direction as before using T7 (IGF I) or T3 (IGF II) polymerase. Samples were subjected to electrophoresis using 6% acrylamide/8.3 M urea DNA sequencing gels. After electrophoresis, gels were dried and exposed to XAR film (Eastman Kodak Co., Rochester, NY). In all experiments, rat liver RNA was included as a positive control. RNA quantities were determined by gel scanning as before (2) .
Other techniques. Protein was measured as before (1 1).
Results
One mechanism by which EGF transmits its "signal" across the plasma membrane of renal collecting duct cells is via activation of phospholipase C (12) . To establish that the potential exists for EGF signal transduction across the plasma membrane of isolated rat renal collecting duct cells, membranes prepared from collecting duct segments were incubated for 15 s in the absence of added peptide or in the presence of 10-10, 10-8, or 10-6 M hEGF. Levels of Ins-P3 were measured in suspensions after chloroform/methanol extraction. As shown in Fig. 1 , addition of 1O-8 or 10-6 M hEGF to suspensions resulted in increased Ins-P3 production (P < 0.01 for each, n = 4, Dunnett's multiple comparison procedure) (13) . Therefore hEGF, like human GH (2), activates phospholipase C in these membranes. In contrast, human prolactin does not activate phospholipase C at this site (2). The concentration dependence for hEGF-stimulated Ins-P3 production in isolated membranes illustrated in Fig. 1 is similar to that shown by Teitelbaum et al. ( 12) , who reported a significant increase of Ins-P3 production upon addition of 10-8 M or higher concentrations of EGF to cultured rat inner medullary collecting tubule cells (12 changed for 2 h of incubation in the absence of added peptide (2) . Addition of hEGF to suspensions of collecting ducts resulted in a concentration-dependent production of IGF I (Fig.  2) . Levels ofIGF I extractable from suspensions incubated with 108 (P < 0.05) and 106 M hEGF (P < 0.01) were significantly elevated compared to levels extractable from suspensions incubated with 0 hEGF (n = 3, Dunnett's multiple comparison procedure). These findings demonstrate that hEGF stimulates production of IGF I in isolated rat renal collecting ducts.
To ascertain whether levels of IGF I mRNA are increased by addition of hEGF to collecting ducts in vitro, we extracted total cellular RNA from collecting ducts incubated with or without 10-6 M hEGF or bGH and measured IGF I mRNA using a solution-hybridization nuclease protection assay. Fig. 3 illustrates that steady-state levels of IGF I mRNA in these cells are increased by hEGF. Levels of IGF I mRNA in collecting ducts were quantitated by gel scanning. Levels in collecting ducts incubated with hEGF were increased by 2.8±0.18-fold (P < 0.01, Student's t test, n = 4) compared to levels in collecting ducts incubated in the absence ofpeptide (100%, control) (Fig.  4) . The increase is comparable to that observed after incubation of collecting ducts with 10-6 M bGH (3.0±0.52-fold) (P < 0.01, Student's t test, n = 6) (Fig. 4) IGF II mRNA is present in small quantities in collecting duct (9) . In contrast to the case for IGF I mRNA, no increase in levels of IGF II mRNA were found after incubation ofcollecting ducts with 10-6 M hEGF as determined by gel scanning, n = 3 experiments (data not shown).
Discussion
The studies described above represent the first demonstration that EGF stimulates IGF I gene expression in the kidney. We and others have shown previously that GH enhances renal IGF I expression (1-3). IGF I of renal origin is likely to play a causative role for the renal hypertrophy observed in hypersomatotropic states (14) . In addition to hypersomatotropism (14) , levels of IGF I in whole kidney (3) (4) (5) and collecting duct (15, 16) are increased in compensatory renal hypertrophy (3, 15, 16) and in diabetic renal hypertrophy (4, 5) . The changes in renal IGF I gene expression in compensatory hypertrophy and diabetes cannot be attributed to GH, since renal IGF I is elevated in compensatory hypertrophy in hypophysectomized rats (3) and since levels of circulating GH are reduced in diabetic rats (6) . Therefore, it is likely that stimuli other than GH regulate IGF I gene expression in kidney in one or both of these conditions and in other settings. The identity of such a stimulus/ stimuli is unknown at present. However, our findings establish the potential for EGF to serve in this capacity.
Mature EGF contains 53 amino acids. It is synthesized as a much larger prepro-EGF precursor consisting of 1, 200 amino acids. The largest quantities of prepro-EGF mRNA in mice and rats are in the submaxillary gland (17) . However, it is next most abundant in kidney, and in other species, levels of prepro-EGF mRNA in kidney are higher than in submaxillary gland (18). The site of EGF synthesis in kidney is the thick ascending limb of Henle's loop and distal tubule as evidenced by the co-presence of prepro-EGF mRNA and immunostainable peptide (7, 17) . EGF in the thick ascending limb ofHenle's loop and distal tubule has been localized histochemically to the luminal membrane (7) . The peptide is also present in extracellular portions of the medullary interstitium (19) . In the mouse submaxillary gland, prepro-EGF is processed intracellularly to the 53-amino acid form of the peptide. In contrast, in kidney cells the precursor accumulates and is not processed to mature EGF (17, 20 liii.-.~~_ age of the extracellular membrane-bound protein by proteases present in the lumen ofthe nephron or in serum would serve to release EGF and account for the large quantity of the peptide present in urine (7) or in medullary interstitium (17, 20 (12, 21) and in freshly isolated suspensions (22) . Teitelbaum et al. (12) reported that EGF stimulates phospholipase C activity in cultured rat inner medullary collecting tubule cells (12) . Harris (21) (25) . Safirstein et al. (26) found reduced renal prepro-EGF mRNA and decreased EGF excretion after induction of ischemic acute renal failure in rats. They suggest that these changes could be a consequence of kidney damage and may reflect the events leading to renal failure or alternatively, and that reduced EGF synthesis is an adaptation permitting restoration ofkidney function (26) . Support for the former hypothesis is provided by Humes et al. (27) and Norman et al. (28) who showed that administration of EGF to rats enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. In view of the action of EGF to enhance IGF I gene expression in collecting duct, it is possible that production of endogenous EGF provides a stimulus for IGF I expression during ischemic renal injury. Alternatively, or in addition, the effect of exogenous EGF to hasten recovery after ischemia could be mediated via enhanced production of IGF I.
